Literature DB >> 21853293

Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.

Takayuki Takimoto1, Tasuku Nakabori, Akio Osa, Satomu Morita, Haruko Terada, Susumu Oseto, Takashi Iwazawa, Kinya Abe.   

Abstract

Renal dysfunction is a characteristic of many patients with cancer; however, a standard therapy has not been established for stage III or IV non-small-cell lung cancer (NSCLC) complicated with chronic renal failure. Docetaxel has a proven significant activity against NSCLC. This agent is predominantly eliminated by hepatobiliary extraction and is safe in patients with renal failure, including dialysis patients. Docetaxel is, thus, a therapeutic option in that patient population. Here, we report acute tubular nephrotoxicity secondary to docetaxel in NSCLC patients, even in patients with normal renal function. Little is known about tubular nephrotoxicity induced by docetaxel; however, oncologists should be aware of its possibility.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21853293     DOI： 10.1007/s10147-011-0304-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


  18 in total

1.  Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.

Authors:  Kathrin Hochegger; Karl Lhotta; Gert Mayer; Martin Czejka; Wolfgang Hilbe
Journal:  Nephrol Dial Transplant       Date:  2006-08-25       Impact factor: 5.992

2.  Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

Authors:  Shinzoh Kudoh; Koji Takeda; Kazuhiko Nakagawa; Minoru Takada; Nobuyuki Katakami; Kaoru Matsui; Tetsu Shinkai; Toshiyuki Sawa; Isao Goto; Hiroshi Semba; Takashi Seto; Masahiko Ando; Taroh Satoh; Naruo Yoshimura; Shunichi Negoro; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

Review 3.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

4.  Pathological complete response induced by first-line chemotherapy with single agent docetaxel in a patient with advanced non small cell lung cancer.

Authors:  Ferdinando Riccardi; Giuseppe Di Lorenzo; Carlo Buonerba; Guglielmo Monaco; Roberto Monaco; Mimma Rizzo; Sarah Scagliarini; Florinda Scognamiglio; Marilena Di Napoli; Giacomo Carteni'
Journal:  World J Surg Oncol       Date:  2010-02-05       Impact factor: 2.754

5.  Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver.

Authors:  M Shou; M Martinet; K R Korzekwa; K W Krausz; F J Gonzalez; H V Gelboin
Journal:  Pharmacogenetics       Date:  1998-10

6.  Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase.

Authors:  J A Kuhn; W P Argy; T A Rakowski; J K Moriarty; G E Schreiner; P S Schein
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

7.  Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.

Authors:  M P Goren; A A Forastiere; R K Wright; M E Horowitz; R K Dodge; B A Kamen; M J Viar; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 8.  Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Authors:  P E Kintzel; R T Dorr
Journal:  Cancer Treat Rev       Date:  1995-01       Impact factor: 12.111

9.  Lung cancer and renal insufficiency: prevalence and anticancer drug issues.

Authors:  Vincent Launay-Vacher; Reza Etessami; Nicolas Janus; Jean-Philippe Spano; Isabelle Ray-Coquard; Stéphane Oudard; Joseph Gligorov; Xavier Pourrat; Philippe Beuzeboc; Gilbert Deray; Jean-François Morere
Journal:  Lung       Date:  2008-10-22       Impact factor: 2.584

10.  Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.

Authors:  Jean-Yves Douillard; Silvy Laporte; Frank Fossella; Vassilis Georgoulias; Jean-Louis Pujol; Kaoru Kubota; Alain Monnier; Shinzoh Kudoh; Jaime Ernesto Rubio; Michel Cucherat
Journal:  J Thorac Oncol       Date:  2007-10       Impact factor: 15.609
View more
  5 in total

1.  Phytantriol Based "Stealth" Lyotropic Liquid Crystalline Nanoparticles for Improved Antitumor Efficacy and Reduced Toxicity of Docetaxel.

Authors:  Sanyog Jain; Neha Bhankur; Nitin K Swarnakar; Kaushik Thanki
Journal:  Pharm Res       Date:  2015-05-13       Impact factor: 4.200

2.  Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer.

Authors:  Shruti Rawal; Vivek Bora; Bhoomika Patel; Mayur Patel
Journal:  Drug Deliv Transl Res       Date:  2020-11-19       Impact factor: 4.617

3.  Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Xinmei Tan; Xueyan Liang; Jiaxi Xi; Sitong Guo; Mingyu Meng; Xiaoyu Chen; Yan Li
Journal:  Medicine (Baltimore)       Date:  2021-09-10       Impact factor: 1.817

4.  Retrospective cohort study on the safety and efficacy of docetaxel in Japanese non-small cell lung cancer patients with nondialysis chronic kidney disease stage 3b or higher.

Authors:  Satoshi Anai; Ritsu Ibusuki; Tomoaki Takao; Yuko Sakurai; Junko Hisasue; Yoichi Takaki; Naohiko Hara
Journal:  Thorac Cancer       Date:  2019-10-21       Impact factor: 3.500

5.  Predisposing Factors for Chemotherapy-induced Nephrotoxicity in Patients with Advanced Esophageal Cancer Who Received Combination Chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil.

Authors:  Junichi Mohri; Chikatoshi Katada; Marie Ueda; Mitsuhiro Sugawara; Keishi Yamashita; Hiromitsu Moriya; Shouko Komori; Kazushige Hayakawa; Wasaburo Koizumi; Koichiro Atsuda
Journal:  J Transl Int Med       Date:  2018-03-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.